Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study

Table 2 Comparative risk for cardiovascular events between dapagliflozin and empagliflozin (reference)

	Dapagliflozin, n (incidence rate)^a	Empagliflozin, n (incidence rate)^a	Crude HR	Adjusted HR
Composite outcome	128 (12.3)	197 (16.3)	0.75 (0.60–0.93)	0.91 (0.73–1.14)
Specific outcome
Cardiovascular mortality	3 (0.3)	7 (0.6)	0.46 (0.12–1.76)	0.54 (0.14–2.12)
Myocardial infarction	33 (3.1)	53 (4.3)	0.70 (0.46–1.09)	0.77 (0.49–1.19)
Ischemic stroke	56 (5.3)	63 (5.2)	1.03 (0.72–1.48)	1.15 (0.80–1.65)
Heart failure	52 (4.9)	109 (9.0)	0.55 (0.39–0.76)	0.68 (0.49–0.95)

ISSN: 1475-2840